title: Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
authors.affiliation: Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia. J.Douglass@alfred.org.au
authors.forename: J A
authors.initials: JA
authors.lastname: Douglass
authors.forename: K
authors.initials: K
authors.lastname: Carroll
authors.forename: A
authors.initials: A
authors.lastname: Voskamp
authors.forename: P
authors.initials: P
authors.lastname: Bourke
authors.forename: A
authors.initials: A
authors.lastname: Wei
authors.forename: R E
authors.initials: RE
authors.lastname: O'Hehir
mesh_terms: D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006323:Heart Arrest / Q000209:etiology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology; D034721:Mastocytosis, Systemic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D000069444:Omalizumab
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab